All Insights

Life Sciences and Healthcare

Will the UK government implement recommendations for the engineering biology sector?

Government responds to recommendations from Lords committee and Regulatory Horizons Council
Unified Patent Court

Infringement claim amendment allowed to include non-UPC territories after CJEU Electrolux decision

Munich local division decided amendment could not be made earlier so allowed Syngenta to extend claim to Czechia, Poland and
Artificial intelligence

Guardians of innovation: US businesses in Europe need to protect trade secrets in the age of AI

Dynamic AI-aware governance frameworks can help safeguard intellectual assets often worth billions of dollars
Intellectual property

European Council adopts negotiating mandate on patents for gene-edited plants

EU moves closer to regulatory change for gene-edited plants but still a long way to go
Intellectual property

Unified Patent Court's Milan Local Division confirms its jurisdiction over cross-border patent infringement claim

UPC applies landmark CJEU ruling again, affirming its ability to adjudicate infringement claims relating to non-UPC European Patents
Intellectual property

Paris Local Division confirms Unified Patent Court as venue for cross-border litigation in Europe and beyond

UPC applies and extends a landmark CJEU ruling, holding it has jurisdiction over an infringement claim relating to non-UPC patents
Life Sciences and Healthcare

EU proposes tailored approach to streamline biosimilar development

New EMA reflection paper signals a step change in biosimilar approval, reducing requirements while maintaining standards
Life Sciences and Healthcare

New regulations signal next step for precision bred plants in England

Government sets out new simplified authorisation process for precision bred organisms
Intellectual property

The year ahead for intellectual property

In an article published in The Licensing Journal, Robyn Trigg looks at the copyright, patent, designs, database rights and trade
Intellectual property

English High Court finds former JV partners misused trade secrets but directors avoid personal liability

The disclosure of confidential information to around 200 investors did not mean it entered the public domain